Anzeige
Meldung des Tages: Kupfer im Fokus: Warum US-Projekte jetzt neu gelesen werden
Werbung
Attraktive Knock-Outs auf Johnson & Johnson Corp
Typ Hebel Bid / Ask WKN
Call
5,0 4,02 € / 4,06 €
FD35V6
Typ Hebel Bid / Ask WKN
Put
4,9 4,13 € / 4,17 €
FD6WW0
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Johnson & Johnson Corp

Johnson & Johnson Aktie News

Aktie
WKN:  853260 ISIN:  US4781601046 US-Symbol:  JNJ Branche:  Pharmazeutika Land:  USA
237,80 $
+3,225 $
+1,37%
201,60 € 05.02.26
Depot/Watchlist
Marktkapitalisierung *
425,07 Mrd. €
Streubesitz
24,80%
KGV
19,04
Dividende
5,14 $
Dividendenrendite
2,92%
neu: Nachhaltigkeits-Score
41 %
Index-Zuordnung
Dow Jones Industrial Average
Weiter aufwärts? Long handeln - Jetzt mit Hebel 6,75: UQ761S
Werbung

Johnson & Johnson News

09.12.25 - PR Newswire
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with ...
06.12.25 - PR Newswire
Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
Earlier use of CARVYKTI® demonstrated lasting treatment-​free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma PR Newswire
05.12.25 - PR Newswire
Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-​free survival at one year in BCG-​unresponsive, high-risk, papillary-​only NMIBC PR ...
03.12.25 - PR Newswire
Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40
Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40 PR Newswire
25.11.25 - LYNX Analysen
Johnson & Johnson: Pharma-Aktie mit weiterem Aufwärtsimpuls – Rallye gewinnt an Dynamik
Johnson & Johnson überzeugt aktuell mit einer starken technischen Entwicklung. Kann die Aktie den Aufwärtstrend weiter fortsetzen? Jetzt vollständige Analyse lesen
24.11.25 - ARIVA.DE Redaktion
Diese 3 defensiven Aktien schlagen jede KI-Korrektur – und Anleger übersehen sie noch
KI-Aktien laufen heiß, weshalb Analysten zu mehr Balance raten im Depot. Welche defensiven Titel jetzt echte Stabilität, starke Dividenden und planbare Cashflows liefern, erklären ...
17.11.25 - PR Newswire
New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis PR Newswire
17.11.25 - ESG-Aktien
Raus aus BioNTech? Rein in Evotec und Vidac Aktie? Was läuft da mit Johnson und Johnson?
Paukenschläge bei Biotechs: Partner Pfizer verkauft seine komplette Beteiligung am deutschen Biotech-​Champion BioNTech. Sollten Anleger es genauso machen? Dagegen liefert ...
07.11.25 - LYNX Analysen
Johnson & Johnson: Der nächste Kursschub könnte anstehen
Die Aktie von Johnson & Johnson konsolidiert auf hohem Niveau. Führt ein Ausbruch über 188 USD zur nächsten Aufwärtsbewegung? Jetzt vollständige Analyse lesen
06.11.25 - PR Newswire
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder PR Newswire
03.11.25 - dpa-AFX
ROUNDUP 2/Trotz Trump-Vorwürfen: Kimberly-Clark übernimmt Tylenol-Hersteller
Mitten in der vom Weißen Haus losgetretenen Kontroverse um das Schmerzmittel Tylenol und Autismus wird der Hersteller Kenvue vom Konsumgüter-​Riesen Kimberly-​Clark ...
03.11.25 - dpa-AFX
ROUNDUP/Trotz Trump-Vorwürfen: Kimberly-Clark übernimmt Tylenol-Hersteller
Mitten in der vom Weißen Haus losgetretenen Kontroverse um das Schmerzmittel Tylenol und Autismus wird der Hersteller Kenvue vom Konsumgüter-​Riesen Kimberly-​Clark ...
03.11.25 - dpa-AFX
Trotz Trump-Vorwürfen: Kimberly-Clark übernimmt Tylenol-Hersteller
Mitten in der vom Weißen Haus losgetretenen Kontroverse um das Schmerzmittel Tylenol und Autismus wird der Hersteller Kenvue vom Konsumgüter-​Riesen Kimberly-​Clark ...
29.10.25 - PR Newswire
Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
Johnson & Johnson announces first head-​to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting PR ...
27.10.25 - PR Newswire
New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile PR Newswire
27.10.25 - PR Newswire
TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years PR ...
27.10.25 - PR Newswire
Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-​daily pill through 28 weeks in ulcerative colitis PR Newswire
24.10.25 - PR Newswire
Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies PR ...
24.10.25 - PR Newswire
Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-​to-treat scalp and genital ...
19.10.25 - PR Newswire
Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer PR Newswire

Newssuche

Videos

newspaper
05.02.26 +8,33%
Technical Trading: Pfund Short im Februar
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »